Magnetic Resonance Imaging Screening In Li Fraumeni Syndrome: An Exploratory Whole Body MRI Study
N/A
18 Years
60 Years
18 Years
60 Years
Open (Enrolling)
Both
Li-Fraumeni Syndrome
Both
Li-Fraumeni Syndrome
Trial Information
Magnetic Resonance Imaging Screening In Li Fraumeni Syndrome: An Exploratory Whole Body MRI Study
Inclusion Criteria:
- Carrier of germline TP53 mutation which, in the view of the geneticist, is not known
to be low penetrance OR non-related individual with no personal history of malignancy
and no first degree relatives diagnosed with malignancy under the age of 50 years
- Age between 18 and 60
- Able to give informed consent
Exclusion Criteria:
- Individual with low penetrance TP53 mutation
- Individual with TP53 variant of unknown significance.
- Previous malignancy diagnosed < 5 years ago in TP53 carriers (except non-melanomatous
skin cancer or cervical CIS) Previous history of malignancy in non-related controls
(except non-melanomatous skin cancer or cervical CIS)
- Current symptoms suggestive of malignancy
- Contraindication to MRI (such as non-MR compatible metal implants) as specified by
the standard MR safety checklist
- Claustrophobia
- ECOG performance status >2
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Outcome Measure:
Diagnosis of malignant disease
Outcome Description:
Following MRI scan further investigations may be required to diagnose malignancy
Outcome Time Frame:
Within 12 months of MRI scan
Safety Issue:
No
Principal Investigator
Rosalind Eeles, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Institute of Cancer Research, Surrey, UK
Authority:
United Kingdom: NHS Health Research Authority
Study ID:
CCR3802
NCT ID:
NCT01737255
Start Date:
October 2012
Completion Date:
Related Keywords:
- Li-Fraumeni Syndrome
- Li-Fraumeni Syndrome
- Whole Body Magnetic Resonance Imaging
- TP53
- Psychological Impact
- Li-Fraumeni Syndrome
Name | Location |
|---|
